Phase 3 Clinical Trials With Primary Completion Dates in November 2017
This is a list of Phase 3 trials with primary completion dates in November 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|AIMT||Aimmune Therapeutics, Inc.||2017-11-01||Phase 3||NCT02635776||Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)|
|ALKS||Alkermes plc||2017-11-01||Phase 3||NCT02696434||Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL|
|ANTH||Anthera Pharmaceuticals, Inc.||2017-11-01||Phase 3||NCT03051490||RESULT: Reliable, Emergent Solution Using Liprotamase Treatment|
|ATRC||AtriCure, Inc.||2017-11-01||Phase 3||NCT02393885||Pivotal Study Of A Dual Epicardial & Endocardial Procedure (DEEP) Approach|
|FGEN||FibroGen, Inc||2017-11-01||Phase 3||NCT01887600||Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis|
|JAZZ||Jazz Pharmaceuticals plc||2017-11-01||Phase 3||NCT02221869||A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy|
|RDY||Dr. Reddy's Laboratories Ltd||2017-11-01||Phase 3||NCT03290027||A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris|
|RDY||Dr. Reddy's Laboratories Ltd||2017-11-01||Phase 3||NCT03009019||Efficacy, Tolerability, and Safety of DFN-15|
|RDY||Dr. Reddy's Laboratories Ltd||2017-11-01||Phase 3||NCT03006276||Efficacy, Tolerability, and Safety Study of DFN-15|